RVTY vs. TEM: Revvity vs. Tempus AI Stock Comparison
How do Revvity (RVTY) and Tempus AI (TEM) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Revvity (RVTY) and Tempus AI (TEM) are both classified in the Life Sciences Tools & Services sub-industry within the broader Life Sciences Tools & Services industry, placing them in the closest GICS peer bucket.
Revvity (RVTY) carries decades of public-market history since February 21, 1973, while Tempus AI (TEM) listed on June 14, 2024 — long-window comparisons have far more historical data on the RVTY side.
| Profile Item | RVTY | TEM |
|---|---|---|
| Name | Revvity Inc. | Tempus AI Inc Class A Common Stock |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Life Sciences Tools & Services | Life Sciences Tools & Services |
| GICS Sub-Industry | Life Sciences Tools & Services | Life Sciences Tools & Services |
| Market Capitalization | 17.31 billion USD | 13.87 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | Nasdaq |
| Listing Date | February 21, 1973 | June 14, 2024 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | RVTY | TEM |
|---|---|---|
| Total Return (1Y) | 76.75% | 16.25% |
| Total Return (3Y, Annualized) | 24.22% | -- |
| Total Return (5Y, Annualized) | -1.48% | -- |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
Tempus AI (TEM) carries a highly aggressive beta of 3.34, indicating much higher sensitivity to broad-market moves, whereas Revvity (RVTY) is closer to market-like at 1.07 — a noticeable difference in market-sensitivity profile.
| Metric | RVTY | TEM |
|---|---|---|
| Volatility (1Y, Annualized) | 40.22% | 76.08% |
| Beta (5Y) | 1.07 | 3.34 |
| Max Drawdown (5Y) | -59.01% | -59.76% |
| Avg. Volume (3M) | 1.89M | 7.20M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | RVTY | TEM |
|---|---|---|
| Sharpe Ratio (1Y) | 1.80 | 0.16 |
| Sortino Ratio (1Y) | 2.90 | 0.26 |
Profitability
ROE (TTM)
Tempus AI (TEM) reports a negative ROE of -37.55%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Revvity (RVTY) reports 3.45%, ranking against industry peers normally.
RVTY
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.45%
- Max
- 109.18%
- Q3
- 6.23%
- RVTY
- 3.45%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
TEM
Pharmaceuticals, Biotechnology & Life Sciences industry group
-37.55%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- TEM
- -37.55%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Tempus AI (TEM) reports a negative net margin of -12.54%, usually indicating a net loss over the period. Meanwhile Revvity (RVTY) reports 8.61%, ranking against industry peers normally.
RVTY
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.61%
- Max
- 18.05%
- RVTY
- 8.61%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
TEM
Pharmaceuticals, Biotechnology & Life Sciences industry group
-12.54%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- TEM
- -12.54%
- Min
- -17.05%
Operating Margin (TTM)
Tempus AI (TEM) reports a negative operating margin of -13.82%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Revvity (RVTY) reports 17.06%, ranking against industry peers normally.
RVTY
Pharmaceuticals, Biotechnology & Life Sciences industry group
17.06%
- Max
- 83.12%
- RVTY
- 17.06%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
TEM
Pharmaceuticals, Biotechnology & Life Sciences industry group
-13.82%
- Max
- 83.12%
- Q3
- 14.77%
- Median
- 0.00%
- TEM
- -13.82%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | RVTY | TEM |
|---|---|---|
| ROE (TTM) | 3.45% | -37.55% |
| ROA (TTM) | 2.54% | -7.36% |
| Net Margin (TTM) | 8.61% | -12.54% |
| Operating Margin (TTM) | 17.06% | -13.82% |
| Gross Margin (TTM) | 55.91% | 64.46% |
Growth
Revenue Growth
Tempus AI (TEM) at 83.41% sits in the top revenue growth quartile, while Revvity (RVTY) at 3.67% is closer to the peer norm — faster top-line expansion for TEM.
EPS Growth
Only one side can be read here: Revvity (RVTY) reports EPS growth of -5.91%, ranked against its industry; Tempus AI (TEM) has no EPS growth figure this period.
Growth Metrics
| Metric | RVTY | TEM |
|---|---|---|
| Revenue Growth (YoY) | 3.67% | 83.41% |
| Revenue Growth (3Y CAGR) | -4.82% | 58.29% |
| EPS Growth (YoY) | -5.91% | -- |
| EPS Growth (3Y CAGR) | -23.26% | -- |
Financial Strength
Current Ratio (MRQ)
Both Revvity (RVTY) at 2.65 and Tempus AI (TEM) at 2.61 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.
RVTY
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.65
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- RVTY
- 2.65
- Q1
- 2.47
- Min
- 0.10
TEM
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.61
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- TEM
- 2.61
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Revvity (RVTY) at 0.38 is near its industry mid-range for debt-to-equity ratio, while Tempus AI (TEM) at 2.86 sits above its benchmark range, pointing to a heavier debt load relative to equity.
RVTY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.38
- Max
- 1.42
- Q3
- 0.65
- RVTY
- 0.38
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
TEM
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.86
- TEM
- 2.86
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | RVTY | TEM |
|---|---|---|
| Current Ratio (MRQ) | 2.65 | 2.61 |
| Debt / Equity (MRQ) | 0.38 | 2.86 |
| Net Debt / EBITDA | 2.43 | -- |
Dividends
Dividend Yield (TTM)
Tempus AI (TEM) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Revvity (RVTY) reports a yield of 0.19%, ranking against industry peers normally.
RVTY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.19%
- RVTY
- 0.19%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
TEM
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- TEM
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Tempus AI (TEM) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Revvity (RVTY) reports a payout of 13.40%, ranking against industry peers normally.
RVTY
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.40%
- RVTY
- 13.40%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
TEM
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- TEM
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | RVTY | TEM |
|---|---|---|
| Dividend Yield (TTM) | 0.19% | 0.00% |
| Dividend Payout Ratio (TTM) | 13.40% | 0.00% |
Valuation
P/E Ratio (TTM)
An earnings multiple is available for just one side: Revvity (RVTY) trades at 68.94 times trailing earnings, ranked against its peers, while Tempus AI (TEM) has no P/E ratio this period.
RVTY
Pharmaceuticals, Biotechnology & Life Sciences industry group
68.94
- Max
- 85.34
- RVTY
- 68.94
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
TEM
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- TEM
- --
P/S Ratio (TTM)
On P/S ratio, both Revvity (RVTY) at 5.88 and Tempus AI (TEM) at 9.19 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
RVTY
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.88
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- RVTY
- 5.88
- Q1
- 3.01
- Min
- 0.01
TEM
Pharmaceuticals, Biotechnology & Life Sciences industry group
9.19
- Max
- 58.18
- Q3
- 25.77
- TEM
- 9.19
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Revvity (RVTY) at 2.39 sits near its industry’s typical P/B ratio, while Tempus AI (TEM) at 27.66 prices above its benchmark range — TEM looks rich relative to book.
RVTY
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.39
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- RVTY
- 2.39
- Q1
- 1.69
- Min
- -5.59
TEM
Pharmaceuticals, Biotechnology & Life Sciences industry group
27.66
- TEM
- 27.66
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | RVTY | TEM |
|---|---|---|
| P/E Ratio (TTM) | 68.94 | -- |
| P/S Ratio (TTM) | 5.88 | 9.19 |
| P/B Ratio (MRQ) | 2.39 | 27.66 |
| Free Cash Flow Yield (TTM) | 3.62% | 0.30% |